LAUSR

Data have been reported from a baselinecontrolled, phase III study of mirabegron in children and adolescents (3–18 years) with neurogenic detrusor overactivity (NDO). Patients received mirabegron at an adult dose equivalent of 25 mg daily, increasing to 50 mg equivalent assuming no safety or tolerability concerns. Between baseline and week 24, a significant increase in maximum cystometric capacity was observed (87.20 ml, 95% CI 66.07–108.33; P < 0.001). Significant increases in bladder compliance, bladder volume until first detrusor contraction, average volume per catheterization, maximum daytime catheterized volume and number of dry days per week were also reported, as well as significant decreases in detrusor pressure and number of leakage episodes per day. Overall, mirabegron was shown to be safe and effective for NDO in a paediatric population.